Contract wins signal continued commercial momentum at life sciences firm

Life sciences business, Aptamer Group, has secured new contracts worth up to £471,000.

Delivering an update an update on contracts signed since its financial year ended 30 June 2024, the York-based company says it has continued the positive commercial traction achieved during the last quarter of the previous financial year.

Its new contracts include multiple agreements, including two from top 20 and one from a top five global pharmaceutical companies, totalling up to £340,000.

These projects are aimed at developing Optimers as critical reagents to support active clinical development programmes and facilitate the analysis of novel therapeutics.

Aptamer develops custom affinity binders through its proprietary Optimer^® platform, which can serve as an alternative to antibodies and enable new approaches in therapeutics, diagnostics, and research applications.

It explains that a significant proportion of its latest deals involve repeat customers who are advancing Aptamer’s binders within their internal pipelines, with some signalling intent for long-term licensing revenues.

Aptamer now has booked revenue contracts of up to £1.2m to recognise throughout FY25 (Jun 25 year-end) and an increased sales pipeline from £2.1m in July 2024 to £4m as of today.

Dr Arron Tolley, chief executive officer, said: “Following the fundraise in August 2024, I am pleased to report that the sustained focus of our commercial team continues to bear fruit.

“We are advancing steadily towards our revenue and potential licensing goals for FY 25 with the best part of seven months left in the financial year.

“Revenue generation and increased income from licensing form a pivotal component of the group’s strategy to deliver shareholder value.”